Regulus Therapeutics
RGLS
#8769
Rank
โ‚ฌ89.84 M
Marketcap
1,37ย โ‚ฌ
Share price
-1.99%
Change (1 day)
4.85%
Change (1 year)

P/E ratio for Regulus Therapeutics (RGLS)

P/E ratio as of November 2024 (TTM): -0.8757

According to Regulus Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.87574. At the end of 2022 the company had a P/E ratio of -0.7366.

P/E ratio history for Regulus Therapeutics from 2012 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-0.7366-24.73%
2021-0.9786-60.13%
2020-2.45203.37%
2019-0.8091387.19%
2018-0.1661-82.34%
2017-0.9405-35.21%
2016-1.45-81.85%
2015-8.00-36.16%
2014-12.5-15.21%
2013-14.89286.92%
2012-0.1575

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
10.5-1,295.80%๐Ÿ‡ฌ๐Ÿ‡ง UK
16.3-1,957.40%๐Ÿ‡ซ๐Ÿ‡ท France
9.42-1,175.83%๐Ÿ‡บ๐Ÿ‡ธ USA
32.6-3,821.36%๐Ÿ‡ฌ๐Ÿ‡ง UK
-66.2 7,463.16%๐Ÿ‡บ๐Ÿ‡ธ USA
-1.95 122.83%๐Ÿ‡บ๐Ÿ‡ธ USA
13.8-1,673.63%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.